BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020;34:985-1005. [PMID: 32055000 DOI: 10.1038/s41375-020-0734-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 36.0] [Reference Citation Analysis]
Number Citing Articles
1 Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC, Tai YT. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers (Basel) 2020;12:E1473. [PMID: 32516895 DOI: 10.3390/cancers12061473] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
2 Zhou X, Einsele H, Danhof S. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. J Clin Med 2020;9:E2166. [PMID: 32659909 DOI: 10.3390/jcm9072166] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
3 Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J 2021;11:84. [PMID: 33927192 DOI: 10.1038/s41408-021-00469-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 2021;12:868. [PMID: 33558511 DOI: 10.1038/s41467-021-21177-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
5 Wang J, Yang J, Kopeček J. Nanomedicines in B cell-targeting therapies. Acta Biomater 2021:S1742-7061(21)00692-9. [PMID: 34687954 DOI: 10.1016/j.actbio.2021.10.024] [Reference Citation Analysis]
6 Abramson HN. Immunotherapy of Multiple Myeloma: Promise and Challenges. Immunotargets Ther 2021;10:343-71. [PMID: 34527606 DOI: 10.2147/ITT.S306103] [Reference Citation Analysis]
7 Davis JA, Shockley A, Hashmi H. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. J Oncol Pharm Pract 2022;:10781552211073517. [PMID: 35006032 DOI: 10.1177/10781552211073517] [Reference Citation Analysis]
8 Costa LJ, Hungria V, Mohty M, Mateos MV. How I treat triple-class refractory multiple myeloma. Br J Haematol 2022. [PMID: 35373352 DOI: 10.1111/bjh.18185] [Reference Citation Analysis]
9 Wei J, Zhao J, Han M, Meng F, Zhou J. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. J Immunother Cancer 2020;8:e000862. [PMID: 32727811 DOI: 10.1136/jitc-2020-000862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
10 Hernández-Rivas JÁ, Ríos-Tamayo R, Encinas C, Alonso R, Lahuerta JJ. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res 2022;10:1. [PMID: 35000618 DOI: 10.1186/s40364-021-00344-2] [Reference Citation Analysis]
11 Saunders CN, Chattopadhyay S, Huhn S, Weinhold N, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Landi S, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Försti A, Houlston R, Hemminki K. Search for AL amyloidosis risk factors using Mendelian randomization. Blood Adv 2021;5:2725-31. [PMID: 34228109 DOI: 10.1182/bloodadvances.2021004423] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Meinl E, Krumbholz M. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma. Curr Opin Immunol 2021;71:117-23. [PMID: 34330018 DOI: 10.1016/j.coi.2021.06.015] [Reference Citation Analysis]
13 Lazaris V, Hatziri A, Symeonidis A, Kypreos KE. The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges. Front Oncol 2021;11:638288. [PMID: 33842343 DOI: 10.3389/fonc.2021.638288] [Reference Citation Analysis]
14 Gao G, Fang M, Xu P, Chen B. Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma. Cancer Med 2021;10:7395-403. [PMID: 34418312 DOI: 10.1002/cam4.4221] [Reference Citation Analysis]
15 Roex G, Campillo-davo D, Flumens D, Shaw PAG, Krekelbergh L, De Reu H, Berneman ZN, Lion E, Anguille S. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03326-6] [Reference Citation Analysis]
16 Zanwar S, Nandakumar B, Kumar S. Immune-based therapies in the management of multiple myeloma. Blood Cancer J 2020;10:84. [PMID: 32829378 DOI: 10.1038/s41408-020-00350-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
17 Dalla Palma B, Marchica V, Catarozzo MT, Giuliani N, Accardi F. Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. J Clin Med 2020;9:E3022. [PMID: 32961764 DOI: 10.3390/jcm9093022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lin WY, Wang HH, Chen YW, Lin CF, Fan HC, Lee YY. Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. Int J Mol Sci 2020;21:E8655. [PMID: 33212810 DOI: 10.3390/ijms21228655] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Dai H, Xu S, Han J, Li Z, Cao J, Hu T, Li H, Wei J, Dou X, Zhou F, Zheng J. Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study. J Affect Disord 2021;286:33-9. [PMID: 33676261 DOI: 10.1016/j.jad.2021.02.041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Dolph M, Tremblay G, Leong H. US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma. Clinicoecon Outcomes Res 2021;13:493-502. [PMID: 34140789 DOI: 10.2147/CEOR.S305830] [Reference Citation Analysis]
21 Domenger A, Choisy C, Baron L, Mayau V, Perthame E, Deriano L, Arnulf B, Bories JC, Dadaglio G, Demangel C. The Sec61 translocon is a therapeutic vulnerability in multiple myeloma. EMBO Mol Med 2022;:e14740. [PMID: 35014767 DOI: 10.15252/emmm.202114740] [Reference Citation Analysis]
22 Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, Quach H, Callander N, Minnema MC, Trudel S, Jackson NA, Ahlers CM, Im E, Cheng S, Smith L, Hareth N, Ferron-Brady G, Brouch M, Montes de Oca R, Paul S, Holkova B, Gupta I, Kremer BE, Richardson P. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncol 2021;17:1987-2003. [PMID: 33682447 DOI: 10.2217/fon-2020-1269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Wang X, He L, Huang X, Zhang S, Cao W, Che F, Zhu Y, Dai J. Recent Progress of Exosomes in Multiple Myeloma: Pathogenesis, Diagnosis, Prognosis and Therapeutic Strategies. Cancers (Basel) 2021;13:1635. [PMID: 33915822 DOI: 10.3390/cancers13071635] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Martino M, Paviglianiti A. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. Expert Opin Biol Ther 2021;21:1025-34. [PMID: 33412948 DOI: 10.1080/14712598.2021.1872540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Banerjee A, McCullough LD. Sex-Specific Immune Responses in Stroke. Stroke 2022;53:1449-59. [PMID: 35468002 DOI: 10.1161/STROKEAHA.122.036945] [Reference Citation Analysis]
26 Simmons GL, Satta T, Castaneda Puglianini O. Clinical experience of CAR T cells for multiple myeloma. Best Pract Res Clin Haematol 2021;34:101306. [PMID: 34625232 DOI: 10.1016/j.beha.2021.101306] [Reference Citation Analysis]
27 Banerjee R, Lo M, Martin TG 3rd. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma. Future Oncol 2021. [PMID: 34553603 DOI: 10.2217/fon-2021-0778] [Reference Citation Analysis]
28 He C, Zhang M, Liu L, Han Y, Xu Z, Xiong Y, Yan F, Su D, Chen H, Zheng Y, Cheng F. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF. Acta Biomater 2022:S1742-7061(22)00105-2. [PMID: 35218967 DOI: 10.1016/j.actbio.2022.02.028] [Reference Citation Analysis]
29 Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma. Clinicoecon Outcomes Res 2020;12:317-25. [PMID: 32606848 DOI: 10.2147/CEOR.S251070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Lopes R, Ferreira BV, Caetano J, Barahona F, Carneiro EA, João C. Boosting Immunity against Multiple Myeloma. Cancers (Basel) 2021;13:1221. [PMID: 33799565 DOI: 10.3390/cancers13061221] [Reference Citation Analysis]
31 Imran S, Neeland MR, Koplin J, Dharmage S, Tang ML, Sawyer S, Dang T, McWilliam V, Peters R, Perrett KP, Novakovic B, Saffery R. Epigenetic programming underpins B-cell dysfunction in peanut and multi-food allergy. Clin Transl Immunology 2021;10:e1324. [PMID: 34466226 DOI: 10.1002/cti2.1324] [Reference Citation Analysis]
32 Allegra A, Di Gioacchino M, Tonacci A, Petrarca C, Musolino C, Gangemi S. Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies. Cells 2021;10:2865. [PMID: 34831088 DOI: 10.3390/cells10112865] [Reference Citation Analysis]
33 Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, Chen S, Pan L. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther 2022;7:39. [PMID: 35132063 DOI: 10.1038/s41392-021-00868-x] [Reference Citation Analysis]
34 Banerjee R, Marsal J, Huang CY, Lo M, Kambhampati S, Kennedy VE, Arora S, Wolf JL, Martin TG, Wong SW, Shah N. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther 2021;27:477.e1-7. [PMID: 33831353 DOI: 10.1016/j.jtct.2021.03.004] [Reference Citation Analysis]
35 Jeryczynski G, Bolomsky A, Agis H, Krauth MT. Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM. Cancers (Basel) 2021;13:5886. [PMID: 34885001 DOI: 10.3390/cancers13235886] [Reference Citation Analysis]
36 Cho SF, Xing L, Anderson KC, Tai YT. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. Cancers (Basel) 2021;13:6136. [PMID: 34885245 DOI: 10.3390/cancers13236136] [Reference Citation Analysis]
37 Uckun FM. Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma. Cancers (Basel) 2021;13:2018. [PMID: 33922005 DOI: 10.3390/cancers13092018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Egan PA, Elder PT, Deighan WI, O'Connor SJM, Alexander HD. Multiple myeloma with central nervous system relapse. Haematologica 2020;105:1780-90. [PMID: 32414852 DOI: 10.3324/haematol.2020.248518] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
39 Khanal N, Chen Z, Alelyunas YW, Szapacs ME, Wrona MD, Sikorski TW. Systematic optimization of targeted and multiplexed MS-based screening workflows for protein biomarkers. Bioanalysis 2022. [PMID: 35255714 DOI: 10.4155/bio-2021-0245] [Reference Citation Analysis]
40 Su CT, Ye JC. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond. J Hematol Oncol 2021;14:115. [PMID: 34301270 DOI: 10.1186/s13045-021-01109-y] [Reference Citation Analysis]
41 Wei W, Zhang Y, Zhang D, Liu Q, An S, Chen Y, Huang G, Liu J. Annotating BCMA Expression in Multiple Myelomas. Mol Pharm 2021. [PMID: 34843261 DOI: 10.1021/acs.molpharmaceut.1c00628] [Reference Citation Analysis]
42 Becnel MR, Lee HC. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol 2020;11:2040620720979813. [PMID: 33403093 DOI: 10.1177/2040620720979813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. How to Treat High-Risk Myeloma at Diagnosis and Relapse. Am Soc Clin Oncol Educ Book 2021;41:291-309. [PMID: 34010042 DOI: 10.1200/EDBK_320105] [Reference Citation Analysis]
44 Tang Y, Yin H, Zhao X, Jin D, Liang Y, Xiong T, Li L, Tang W, Zhang J, Liu M, Yu Z, Liu H, Zang S, Huang Z. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J Exp Clin Cancer Res 2022;41:2. [PMID: 34980210 DOI: 10.1186/s13046-021-02214-z] [Reference Citation Analysis]
45 McMillan A, Warcel D, Popat R. Antibody-drug conjugates for multiple myeloma. Expert Opin Biol Ther 2021;21:889-901. [PMID: 32729730 DOI: 10.1080/14712598.2020.1802422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
46 Brechbühl S, Bacher U, Jeker B, Pabst T. Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy. Mediterr J Hematol Infect Dis 2021;13:e2021012. [PMID: 33489051 DOI: 10.4084/MJHID.2021.012] [Reference Citation Analysis]
47 Da Vià MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, Zhou X, Danhof S, Kraus S, Chatterjee M, Meggendorfer M, Twardziok S, Goebeler ME, Topp MS, Hudecek M, Prommersberger S, Hege K, Kaiser S, Fuhr V, Weinhold N, Rosenwald A, Erhard F, Haferlach C, Einsele H, Kortüm KM, Saliba AE, Rasche L. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med 2021;27:616-9. [PMID: 33619368 DOI: 10.1038/s41591-021-01245-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
48 Peng F, Wang Y, Zhao J, Liu H, Liu Z, Ding K, Zhang H, Fu R. Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma. Br J Haematol 2022. [PMID: 35594370 DOI: 10.1111/bjh.18230] [Reference Citation Analysis]
49 Sperling AS, Anderson KC. Facts and Hopes in Multiple Myeloma Immunotherapy. Clin Cancer Res 2021;27:4468-77. [PMID: 33771856 DOI: 10.1158/1078-0432.CCR-20-3600] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Moore JD. Therapeutic cancer vaccines: reasons to believe. Emerg Top Life Sci 2021;5:591-5. [PMID: 34495328 DOI: 10.1042/ETLS20210205] [Reference Citation Analysis]
51 Mohyuddin GR, Banerjee R, Alam Z, Berger KE, Chakraborty R. Rethinking mechanisms of neurotoxicity with BCMA directed therapy. Crit Rev Oncol Hematol 2021;166:103453. [PMID: 34461271 DOI: 10.1016/j.critrevonc.2021.103453] [Reference Citation Analysis]
52 Tai W, Wahab A, Franco D, Shah Z, Ashraf A, Abid Q, Mohammed YN, Lal D, Anwer F. Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma. Antibodies 2022;11:22. [DOI: 10.3390/antib11020022] [Reference Citation Analysis]
53 Lederer CW, Koniali L, Buerki-thurnherr T, Papasavva PL, La Grutta S, Licari A, Staud F, Bonifazi D, Kleanthous M. Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies. Pharmaceutics 2022;14:793. [DOI: 10.3390/pharmaceutics14040793] [Reference Citation Analysis]
54 Xiang X, He Q, Ou Y, Wang W, Wu Y. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials. Front Pharmacol 2020;11:544754. [PMID: 33343342 DOI: 10.3389/fphar.2020.544754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Li GQ, Wang YK, Zhou H, Jin LG, Wang CY, Albahde M, Wu Y, Li HY, Zhang WK, Li BH, Ye ZM. Application of Immune Infiltration Signature and Machine Learning Model in the Differential Diagnosis and Prognosis of Bone-Related Malignancies. Front Cell Dev Biol 2021;9:630355. [PMID: 33937231 DOI: 10.3389/fcell.2021.630355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Simon S, Riddell SR. Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. Blood Cancer Discov 2020;1:130-3. [PMID: 34661143 DOI: 10.1158/2643-3230.BCD-20-0122] [Reference Citation Analysis]
57 Maples KT, Joseph NS, Harvey RD. Current developments in the combination therapy of relapsed/refractory multiple myeloma. Expert Rev Anticancer Ther 2020;20:1021-35. [PMID: 32969752 DOI: 10.1080/14737140.2020.1828071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Nishida H. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers (Basel) 2021;13:2712. [PMID: 34072645 DOI: 10.3390/cancers13112712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Musto P, La Rocca F. Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence. Expert Rev Hematol 2020;13:501-17. [PMID: 32290723 DOI: 10.1080/17474086.2020.1753502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma. Drugs Context 2021;10:2021-2-4. [PMID: 34603459 DOI: 10.7573/dic.2021-2-4] [Reference Citation Analysis]
61 Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol 2021;11:656218. [PMID: 34041025 DOI: 10.3389/fonc.2021.656218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
62 Sanchez L, Dardac A, Madduri D, Richard S, Richter J. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. Ther Adv Hematol 2021;12:2040620721989585. [PMID: 33796236 DOI: 10.1177/2040620721989585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
63 Barilà G, Rizzi R, Zambello R, Musto P. Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf. Pharmaceuticals (Basel) 2021;14:40. [PMID: 33430210 DOI: 10.3390/ph14010040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Ishibashi M, Morita R, Tamura H. Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma. Cancers (Basel) 2021;13:E279. [PMID: 33451089 DOI: 10.3390/cancers13020279] [Reference Citation Analysis]
65 Braunlin M, Belani R, Buchanan J, Wheeling T, Kim C. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data. Leuk Lymphoma 2021;62:377-86. [PMID: 33026271 DOI: 10.1080/10428194.2020.1827253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 2021;18:71-84. [PMID: 32978608 DOI: 10.1038/s41571-020-0427-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
67 Xu S, Lam KP. Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma? Cancers (Basel) 2020;12:E1045. [PMID: 32340409 DOI: 10.3390/cancers12041045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
68 Susanibar Adaniya S, Stadtmauer EA, Cohen AD. CAR T cell therapy for multiple myeloma: What have we learned? Leukemia. [DOI: 10.1038/s41375-022-01539-8] [Reference Citation Analysis]
69 Paul B, Rodriguez C, Usmani SZ. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. Drugs 2022. [PMID: 35412114 DOI: 10.1007/s40265-022-01697-0] [Reference Citation Analysis]
70 Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther 2021;6:412. [PMID: 34897277 DOI: 10.1038/s41392-021-00823-w] [Reference Citation Analysis]
71 Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, Chu Y, Berneman ZN, Lion E, Luo F, Anguille S. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol 2020;13:164. [PMID: 33272302 DOI: 10.1186/s13045-020-01001-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
72 Abramson HN. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci 2020;21:E5192. [PMID: 32707894 DOI: 10.3390/ijms21155192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
73 Chalopin T, Vallet N, Theisen O, Ochmann M, Tiab M, Godmer P, Barin C, Hérault O, Gyan E, Le Gouill S, Avet-Loiseau H, Benboubker L, Moreau P, Touzeau C. No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. Br J Haematol 2021;194:635-8. [PMID: 33928635 DOI: 10.1111/bjh.17488] [Reference Citation Analysis]
74 Fernando RC, de Carvalho F, Leme AFP, Colleoni GWB. Tumor Microenvironment Proteomics: Lessons From Multiple Myeloma. Front Oncol 2021;11:563384. [PMID: 33833982 DOI: 10.3389/fonc.2021.563384] [Reference Citation Analysis]
75 Kaufman GP, Cerchione C. Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis. Front Oncol 2020;10:624573. [PMID: 33614504 DOI: 10.3389/fonc.2020.624573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
76 Nathwani N, Bertamini L, Banerjee R, Gay F, Shah N, Krishnan A. When and How to Treat Relapsed Multiple Myeloma. Am Soc Clin Oncol Educ Book 2021;41:358-75. [PMID: 34010043 DOI: 10.1200/EDBK_320129] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Alhallak K, Sun J, Jeske A, Park C, Yavner J, Bash H, Lubben B, Adebayo O, Khaskiah A, Azab AK. Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. Cancers (Basel) 2021;13:2853. [PMID: 34201007 DOI: 10.3390/cancers13122853] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Bujarski S, Sutanto C, Spektor TM, To J, Swift RA, Green T, Eades BR, Emamy-Sadr M, Souther E, Berenson JR. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. Hematol Oncol 2022. [PMID: 34982491 DOI: 10.1002/hon.2961] [Reference Citation Analysis]
79 Fotiou D, Ntanasis-stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Multiple myeloma: Current and future management in the aging population. Maturitas 2020;138:8-13. [DOI: 10.1016/j.maturitas.2020.04.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Seipel K, Porret N, Wiedemann G, Jeker B, Bacher VU, Pabst T. sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma. CIMB 2022;44:1463-71. [DOI: 10.3390/cimb44040098] [Reference Citation Analysis]
81 Constantinescu C, Pasca S, Zimta AA, Tat T, Rus I, Teodorescu P, Iluta S, Tanase A, Colita A, Sigurjonsson O, Einsele H, Tomuleasa C. Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies. J Clin Med 2020;9:E2903. [PMID: 32911829 DOI: 10.3390/jcm9092903] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Mohan M, Maatman TC, Schinke C. The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma. Cancers (Basel) 2021;13:4909. [PMID: 34638393 DOI: 10.3390/cancers13194909] [Reference Citation Analysis]
83 Lassiter G, Bergeron C, Guedry R, Cucarola J, Kaye AM, Cornett EM, Kaye AD, Varrassi G, Viswanath O, Urits I. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Curr Oncol 2021;28:640-60. [PMID: 33494319 DOI: 10.3390/curroncol28010063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
84 Marella M, Yao X, Carreira V, Bustamante MF, Clark HB, Jackson CC, Zudaire E, Schecter JM, Glover TD, Shenton J, Cornax I. Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy. J Histochem Cytochem 2022;:221554221079579. [PMID: 35193424 DOI: 10.1369/00221554221079579] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Hartley-brown M, Richardson P. Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon? Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00067] [Reference Citation Analysis]
86 Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, Teruya-Feldstein J, Crary JF, Fowkes ME, Stacy CB, Kim-Schulze S, Rahman A, Laganà A, Brody JD, Merad M, Jagannath S, Parekh S. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med 2021;27:2099-103. [PMID: 34893771 DOI: 10.1038/s41591-021-01564-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in Multiple Myeloma-A Promising Key to Therapy. J Clin Med 2021;10:4088. [PMID: 34575199 DOI: 10.3390/jcm10184088] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Strassl I, Schreder M, Steiner N, Rudzki J, Agis H, Künz T, Müser N, Willenbacher W, Petzer A, Neumeister P, Krauth MT. The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. Cancers (Basel) 2021;13:4701. [PMID: 34572927 DOI: 10.3390/cancers13184701] [Reference Citation Analysis]
89 Dogan A, Siegel D, Tran N, Fu A, Fowler J, Belani R, Landgren O. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J 2020;10:73. [PMID: 32606424 DOI: 10.1038/s41408-020-0337-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
90 Tran S, Truong TH, Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. Eur J Cancer 2021;159:259-74. [PMID: 34798454 DOI: 10.1016/j.ejca.2021.10.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Rodríguez-Otero P, Prósper F, Alfonso A, Paiva B, San Miguel JF. CAR T-Cells in Multiple Myeloma Are Ready for Prime Time. J Clin Med 2020;9:E3577. [PMID: 33172026 DOI: 10.3390/jcm9113577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
92 Mann H, Katiyar V, Varga C, Comenzo RL. Smoldering multiple myeloma - Past, present, and future. Blood Rev 2021;:100869. [PMID: 34312016 DOI: 10.1016/j.blre.2021.100869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Rodriguez-Otero P, Ayers D, Cope S, Davies FE, Delforge M, Mojebi A, Jansen JP, Weisel K, Hege K, Dhanasiri S. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Leuk Lymphoma 2021;:1-10. [PMID: 33896344 DOI: 10.1080/10428194.2021.1913143] [Reference Citation Analysis]
94 Uckun FM. Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma. Front Oncol 2021;11:760382. [PMID: 34858838 DOI: 10.3389/fonc.2021.760382] [Reference Citation Analysis]
95 Hartley-Brown M, Chitty D, Thakur R. Monoclonal Antibodies in Myeloma: Optimizing Targeted Therapy. Cancer J 2021;27:222-30. [PMID: 34549911 DOI: 10.1097/PPO.0000000000000521] [Reference Citation Analysis]
96 Chng WJ. New immunotherapeutic target in myeloma. Blood 2022;139:2417-8. [PMID: 35446380 DOI: 10.1182/blood.2022015481] [Reference Citation Analysis]
97 Ma W, Pan B, Zhang L. Gastric Cancer or Plasmacytoma in a Seemingly Well-Controlled Multiple Myeloma Patient? Turk J Haematol 2021;38:169-70. [PMID: 33557002 DOI: 10.4274/tjh.galenos.2021.2020.0645] [Reference Citation Analysis]
98 Zhang L, Wang Y, Xu KL. [Mechanisms and prevention strategies of relapse and resistance after BCMA-CAR-T cell in multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2021;42:778-81. [PMID: 34753237 DOI: 10.3760/cma.j.issn.0253-2727.2021.09.014] [Reference Citation Analysis]
99 Romano A, Storti P, Marchica V, Scandura G, Notarfranchi L, Craviotto L, Di Raimondo F, Giuliani N. Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. Front Oncol 2021;11:684561. [PMID: 34307150 DOI: 10.3389/fonc.2021.684561] [Reference Citation Analysis]